Symbols

CHRS

Coherus Oncology·NASDAQ

--(--)

Signals Analysis

Bullish signal 2

Bearish signal 2

Consensus Rating "Buy"

High Gross Profit Margin

EPS Below Expectations

Revenue Below Expectations

Key Stats

0.0000DAY`S RANGE0.0000

0.000052 WK RANGE0.0000

Open

0.0000

Prev.Close

0.0000

%Range

Turnover

Avg Vol(4W)

Market Cap

Div.Yield

P/E(TTM)

EPS(TTM)

Beta

Free Float

Shares Outstanding

%Turnover

P/E(DYN)

P/B

BVPS

High

0.0000

Low

0.0000

52 Week High

0.0000

52 Week Low

0.0000

About CHRS

Coherus Oncology, Inc.

A commercial stage biopharmaceutical company that builds a leading immuno-oncology franchise

Industry

Pharmaceutical

Established Date

Listing Date

11/06/2014

Exchange

NASDAQ Stock Exchange

Full-time Employees

147

Fiscal Year Ends

12-31

Website

www.coherus.com

Security Type

Common stock

Office address

333 Twin Dolphin Drive, Suite 600, Redwood City, California 94065

Business

Introduction

Coherus Oncology, Inc., was incorporated in Delaware in September 2010. The Company is a commercial-stage biopharmaceutical company focused on the research, development and commercialization of innovative cancer treatments and the commercialization of approved biosimilar combinations. The company's strategy is to build a leading immuno-oncology franchise, funded by cash generated through net sales of a diverse portfolio of U.S. Food and Drug Administration-approved therapies.

Company Financials

EPS

CHRS has released its 2025 Q4 earnings. EPS was reported at -0.34, versus the expected -0.34, meeting expectations. The chart below visualizes how CHRS has performed over recent quarters, highlighting trends in earnings surprises.

Revenue & Expenses

CHRS has released its 2025 Q4 earnings report, with revenue of 12.75M, reflecting a YoY change of 64.85%, and net profit of -37.64M, showing a YoY change of 25.75%. The Sankey diagram below clearly presents CHRS's revenue sources and cost distribution.